A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)

被引：0

作者：

O'Cearbhaill, Roisin ^{[1
]}

Sill, Michael ^{[2
]}

Duong, Hoa ^{[3
]}

Waggoner, Steven ^{[4
]}

Grisham, Rachel ^{[1
]}

Backes, Floor ^{[5
]}

Mannel, Robert ^{[6
]}

Tanyi, Janos ^{[7
]}

Powell, Matthew ^{[8
]}

Mathews, Cara ^{[9
]}

Ghamande, Sharad ^{[10
]}

Mcnally, Leah ^{[11
]}

Olawaiye, Alexander ^{[12
]}

Bender, David ^{[13
]}

Duska, Linda ^{[14
]}

Lankes, Heather ^{[15
]}

Zamarin, Dmitriy ^{[16
]}

Schilder, Russell ^{[17
]}

Bookman, Michael ^{[18
]}

Aghajanian, Carol ^{[1
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

[2] NRG Oncol Stat & Data Management Ctr, Biostat & Bioinformat Dept, Buffalo, NY USA

[3] Kaiser Permanente Sacramento, Hematol Oncol, Sacramento, CA USA

[4] CWRU Case Comprehens Canc Ctr, Gynecol Oncol, Cleveland, OH USA

[5] Ohio State Univ, Comprehens Canc Ctr, Gynecol Oncol, Columbus, OH USA

[6] Univ Oklahoma, Hlth Sci Ctr, Obstet & Gynecol, Oklahoma City, OK USA

[7] Univ Penn, Abramson Canc Ctr, Obstet & Gynecol, Philadelphia, PA 19104 USA

[8] Washington Univ, Gynecol Oncol, St Louis, MO 63110 USA

[9] Women & Infants Hosp Rhode Isl, Obstet & Gynecol, Providence, RI USA

[10] Georgia Cares Minor Underserved NCORP, Gynecol Oncol, Augusta, GA USA

[11] Duke Canc Inst, Gynecol Oncol, Durham, NC USA

[12] UPMC Hillman Canc Ctr, Gynecol Oncol, Pittsburgh, PA USA

[13] Univ Iowa, Obstet & Gynecol, Iowa City, IA USA

[14] Univ Virginia, Gynecol Oncol, Canc Ctr, Charlottesville, VA USA

[15] NRG Oncol Biospecimen Bank Columbus, Translat Sci Operat, Columbus, OH USA

[16] Icahn Sch Med Mt Sinai, Hematol Oncol, New York, NY 10029 USA

[17] Thomas Jefferson Univ, Gynecol Med Oncol, Philadelphia, PA 19107 USA

[18] Kaiser Permanente Northern Calif, Gynecol Oncol, San Francisco, CA USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO005LBA

引用

页码：A4 / A4

页数：1

共 50 条

[1] Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
Vergote, Ignace
Finkler, Neil J.
Hall, James B.
Melnyk, Ostap
Edwards, Robert P.
Jones, Marsha
Keck, James G.
Meng, Lisa
Brown, Gail L.
Rankin, Elaine M.
Burke, James J.
Boccia, Ralph V.
Runowicz, Carolyn D.
Rose, Peter G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (05) : 772 - 780
[2] Carboplatin, pegylated liposomal Doxorubicin, and Bevacizumab in Ovarian Cancer
Gappa, Birgit
GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (08)
[3] Pegylated liposomal doxorubicin with bevacizumab in the treatment of platinum-resistant ovarian cancer: Toxicity profile results
Czok, S.
Jewell, A.
Shawki, S.
Boyd, L.
Smith, H.
Blank, S.
Muller, C.
Verschraegen, C.
Muggia, F.
GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S83 - S83
[4] Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Mo, Dun-Chang
Ren, Tao
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) : 522 - +
[5] Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer
Verhaar-Langereis, M
Karakus, A
Van Eijkeren, M
Voest, E
Witteveen, E
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) : 65 - 70
[6] Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
Michels, Judith
Ghiringhelli, Francois
Frenel, Jean-Sebastien
Brard, Caroline
You, Benoit
Floquet, Anne
Eberst, Lauriane
Bahleda, Rastilav
Genestie, Catherine
Balleyguier, Corinne
Broutin, Sophie
Pautier, Patricia
Colomba, Emeline
Pommeret, Fanny
Massard, Christophe
Marabelle, Aurelien
Leary, Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer Reply
Hamanishi, Junzo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) : 523 - 524
[8] Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer The APPROVE Randomized Clinical Trial
Wang, Tiantian
Tang, Jie
Yang, Hongying
Yin, Rutie
Zhang, Jingru
Zhou, Qi
Liu, Ziling
Cao, Lanqin
Li, Li
Huang, Yi
Jiang, Kui
Wang, Wei
She, Fenglin
Guan, Ni
Hou, Zhiguo
Li, Ning
Wu, Lingying
JAMA ONCOLOGY, 2022, 8 (08) : 1169 - 1176
[9] Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
Pujade-Lauraine, E.
Fujiwara, K.
Ledermann, J. A.
Oza, A. M.
Kristeleit, R. S.
Ray-Coquard, I. L.
Richardson, G. E.
Sessa, C.
Yonemori, K.
Banerjee, S.
Leary, A.
Tinker, A. V.
Jung, K. H.
Madry, R.
Park, S. Y.
Anderson, C. K.
Zohren, F.
Stewart, R.
Wei, C.
Dychter, S. S.
Monk, B. J.
GYNECOLOGIC ONCOLOGY, 2019, 154 : 21 - 22
[10] Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
Mutch, David G.
Orlando, Mauro
Goss, Tiana
Teneriello, Michael G.
Gordon, Alan N.
McMeekin, Scott D.
Wang, Yanping
Scribner, Dennis R., Jr.
Marciniack, Martin
Naumann, R. Wendel
Secord, Angeles Alvarez
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) : 2811 - 2818

← 1 2 3 4 5 →